drugset
drugset / Trial / NCT05421325

Efficacy of QBKPN Site-Specific Immunomodulator in Improving Innate Immune Function & Reducing Respiratory Tract Infection in Older Adults

NCT05421325 ↗

Phase 2 Recruiting 72 enrolled Qu Biologics Inc. The National Research Council of Canada Industrial Research Assistance Program · collab
RandomizedParallel-groupQuadruple-blindPrevention

Summary

This study is designed to test whether QBKPN SSI can improve immune function in older adults, including how well it can protect against respiratory and other infections, whether it improves the body's response to COVID-19 vaccines, what effect it has on maintaining or improving quality of life, activity level and health status and whether it has an effect on glycemic control. QBKPN is a new medication in a class known as Site-Specific Immunomodulators (SSI). SSIs are designed to train and/or improve innate immune function to reduce the risk of infections, improve immune response to cancer, and slow the progression of chronic inflammatory diseases. It is believed that QBKPN SSI can work with the immune system to help protect against respiratory and other infections.

Timeline

Start
2023-04-11
Primary completion
2025-09
Completion
2026-02

Drugs

EvaluationDrugModalityDoseRoute
Subject QBKPN Unknown 0.1 ml Subcutaneous

Indications

immunodeficiency disease